User profiles for Matthew D Snape
 | MD SnapeConsultant in Paediatrics and Vaccinology, University of Oxford Verified email at paediatrics.ox.ac.uk Cited by 25036 |
[HTML][HTML] Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a …
Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa …
Background A safe and efficacious vaccine against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …
[HTML][HTML] Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind …
Background Older adults (aged ≥70 years) are at increased risk of severe disease and
death if they develop COVID-19 and are therefore a priority for immunisation should an …
death if they develop COVID-19 and are therefore a priority for immunisation should an …
[HTML][HTML] Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV …
Background Few data exist on the comparative safety and immunogenicity of different
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of …
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of …
Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial
MD Snape, KP Perrett, KJ Ford, TM John, D Pace… - Jama, 2008 - jamanetwork.com
Context Immunization with a meningococcal tetravalent (serogroup ACWY) glycoconjugate
vaccine is recommended for all US adolescents. However, the currently licensed vaccine is …
vaccine is recommended for all US adolescents. However, the currently licensed vaccine is …
[HTML][HTML] Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised …
Background A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of
COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy …
COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy …
Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
There is significant international interest in heterologous prime-boost COVID-19 vaccination
to mitigate against supply shocks or shortages that might otherwise reduce the speed of …
to mitigate against supply shocks or shortages that might otherwise reduce the speed of …
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a …
…, LL Walker, R White, JS Nguyen-Van-Tam, MD Snape… - The Lancet, 2021 - thelancet.com
Background Use of heterologous prime-boost COVID-19 vaccine schedules could facilitate
mass COVID-19 immunisation. However, we have previously reported that heterologous …
mass COVID-19 immunisation. However, we have previously reported that heterologous …
[HTML][HTML] T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of
Coronavirus Disease 2019 (COVID-19), has caused a global pandemic, and safe, effective …
Coronavirus Disease 2019 (COVID-19), has caused a global pandemic, and safe, effective …
Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial
MD Snape, T Dawson, P Oster, A Evans… - The Pediatric …, 2010 - journals.lww.com
Background: An investigational vaccine against serogroup B meningococcal (MenB) disease
containing 3 main recombinant proteins (factor H-binding protein, Neisserial adhesion A, …
containing 3 main recombinant proteins (factor H-binding protein, Neisserial adhesion A, …
